Randomized, Single Dose, Two Way, Cross-Over Open-Label Study To Determine The Pharmacokinetic Parameters Of AFT Pharmaceuticals Ltd Test Product Ferro-C (325 mg Ferrous Sulfate And 562.4 mg Sodium Ascorbate Per Modified Release Tablet) Relative To BGP Products Pty Ltd Reference Product FERRO-GRAD C® (325 mg Ferrous Sulfate And 562.4 mg Sodium Ascorbate Per Modified Release Tablet), After Oral Administration In 24 Healthy Adult Volunteers Under Fasting and Fed Conditions

Start Date27 Apr 2019

Sponsor / Collaborator

AFT Pharmaceuticals Ltd.

100 Clinical Results associated with FE-C

100 Translational Medicine associated with FE-C

100 Patents (Medical) associated with FE-C

Literatures (Medical) associated with FE-C

01 Jul 2024·Food Research International

Intestinal delivery of encapsulated bacteriocin peptides in cross-linked alginate microcapsules

Article

Author: Marco, Maria L ; Jeoh, Tina ; Wei, Lei ; Wong, Dana

Oral delivery of larger bioactive peptides (>20 amino acids) to the small intestine remains a challenge due to their sensitivity to proteolytic degradation and chemical denaturation during gastrointestinal transit. In this study, we investigated the capacity of crosslinked alginate microcapsules (CLAMs) formed by spray drying to protect Plantaricin EF (PlnEF) (C-EF) in gastric conditions and to dissolve and release PlnEF in the small intestine. PlnEF is an unmodified, two-peptide (PlnE: 33 amino acids; PlnF: 34 amino acids) bacteriocin produced by Lactiplantibacillus plantarum with antimicrobial and gut barrier protective properties. After 2 h incubation in simulated gastric fluid (SGF) (pH 1.5), 43.39 % ± 8.27 % intact PlnEF was liberated from the CLAMs encapsulates, as determined by an antimicrobial activity assay. Transfer of the undissolved fraction to simulated intestinal fluid (SIF) (pH 7) for another 2 h incubation resulted in an additional release of 16.13 % ± 4.33 %. No active PlnEF was found during SGF or sequential SIF incubations when pepsin (2,000 U/ml) was added to the SGF. To test PlnEF release in C-EF contained in a food matrix, C-EF was mixed in peanut butter (PB) (0.15 g C-EF in 1.5 g PB). A total of 12.52 % ± 9.09 % active PlnEF was detected after incubation of PB + C-EF in SGF without pepsin, whereas no activity was found when pepsin was included. Transfer of the remaining PB + C-EF fractions to SIF yielded the recovery of 46.67 % ± 13.09 % and 39.42 % ± 11.53 % active PlnEF in the SIF following exposure to SGF and to SGF with pepsin, respectively. Upon accounting for the undissolved fraction after SIF incubation, PlnEF was fully protected in the CLAMs-PB mixture and there was not a significant reduction in active PlnEF when pepsin was present. These results show that CLAMs alone do not guard PlnEF bacteriocin peptides from gastric conditions, however, mixing them in PB protected against proteolysis and improved intestinal release.

01 Jan 2023·Chemosphere

Micro-polluted water resources treatment by PVDF-TiO2 membrane combined with Fe2+/sodium dithionite (DTN)/O2 pre-oxidation process

Article

Author: Zhang, Xiaolei ; Sun, Feiyun ; Song, Wei ; Dong, Wenyi ; Xie, Wanying ; Li, Ji

Modifying PVDF membrane by blending hydrophilic nano TiO₂ has been highly concerning, but its practical application is not well investigated. In this study, PVDF-TiO₂ membrane was employed in two modes to treat micro-polluted raw water for the first time, direct membrane filtration and pre-oxidation assists membrane filtration. At two filtration modes, the PVDF-TiO₂ membrane had comparable rejection capability to the unmodified PVDF membrane, as the removal of permanganate index (COD_Mn) was 0.26-0.72 mg/L, UV₂₅₄ was 0.0070-0.0618 cm^-1, turbidity was 1.60-4.49 NTU, and the total number of colonies was 360-23,780 CFU/mL. As for raw water treatment, using Fe²⁺/sodium dithionite (DTN)/O₂ system as the pre-oxidation process to assist the filtration of the PVDF-TiO₂ membrane was feasible. After optimization, the applicable conditions of the Fe²⁺/DTN/O₂ process were DTN dosage at 100 mg/L and a C_Fe/C_DTN of 1:4. As a result, the effluent qualities of the PVDF-TiO₂ membrane significantly improved. It was investigated that atrazine (ATZ), COD_Mn, UV_254, and turbidity reduced, which was realized by the synergic effects of the pre-oxidation by free radicals and flocculation by iron. Pre-oxidation of the Fe²⁺/DTN/O₂ process could also enhance the permeability of the PVDF-TiO₂ membrane from 53.6 to 58.0 L/(m²·h), nearly two times the PVDF membrane. Besides, the practical fouling of the PVDF-TiO₂ membrane was stably alleviated by the reduced R_t, R_re, and R_ir, mainly due to constraining the internal pore fouling effectively.

01 Nov 2022·Carbohydrate Polymers

Fe-complex modified cellulose acetate composite membrane with excellent photo-Fenton catalytic activity

Article

Author: Yang, Jing ; Wang, Dawei ; Shi, Zhengjun ; Yang, Haiyan ; Zhao, Ping

A novel Fe-complex loaded visible-light active cellulose acetate (CA) composite membrane (Fe-complex/CA) was fabricated using the tape casting method. The Fe-complex was structurally characterized by single-crystal X-ray diffraction, and the prepared composite membrane was characterized by SEM, XPS, XRD, FTIR and UV-Vis diffuse reflectance spectroscopy. The Fe-complex/CA composite membrane exhibited relatively good visible light photocatalytic activity toward organic dyes and sulfadiazine antibiotics in the presence of low concentrations of H₂O₂. After irradiation for 60 min, the degradation efficiencies of basic fuchsin, methylene blue and sulfadiazine reached 100 %, 93.4 % and 95.7 %, respectively. The composite membrane maintained good photocatalytic activity after four catalytic cycles. Kinetic studies showed that the degradation processes of basic fuchsin, methylene blue and sulfadiazine were all in accordance with first-order reaction kinetics. In addition, the photocatalytic mechanism of the Fe-complex/CA composite membrane in the photo-Fenton reaction was also discussed in detail.

100 Deals associated with FE-C

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia, Iron-Deficiency	Phase 1	-	Abiogen Pharma SpA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2010	Not Applicable	Locally advanced breast cancer Neoadjuvant	34	Neoadjuvant FEC-C therapy	(efxphlwqjq) = wawtahkvli yfmuenegxo (gmymprmylv )	-	15 Apr 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

FE-C

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation